NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502 

An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results allow for the further development of the program to Phase 1  Utrecht, the Netherlands, and Lyon, France, 8 June 2022  Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces the completion and positive results of toxicology studies for

learn more

Antibiotic resistance: Nosopharm and the University of Illinois at Chicago describe mechanism of action of new class of antibiotics in Molecular Cell

Newly discovered antibiotic binds to ribosome and disrupts protein synthesis Lyon, France, and Chicago (IL), United States – April 5 2018 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University of Illinois at Chicago (UIC) today announce the publication of a study in Molecular Cell on the mechanism of action of odilorhabdins, a new class of antibiotics to combat antibiotic resistance. The antibiotic, first identified by Nosopharm,

learn more

Nosopharm shares scientific data on Odilorhabdins, a novel antibacterial class with the potential to combat antibiotic resistance

During the ICAAC, Washington DC, September 5-9, Nosopharm will welcome partner enquiries to co-develop Odilorhabdins Nîmes, France, September 3, 2014 – Nosopharm, a specialist in the research and development of new anti-infective drugs, announces today its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance. This new scientific data will be shared at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on

learn more